KEY POINTS
- TrumpRx.gov provides discounts on forty high cost prescription drugs at most favored nation prices.
- Five major drugmakers have joined initial pricing agreements with the administration.
- The initiative aims to reduce out of pocket costs and rebalance global drug pricing.
President Donald Trump on Tuesday announced the launch of TrumpRx.gov, a federal website designed to give US patients access to steep discounts on brand name prescription drugs by aligning prices with the lowest paid in other developed nations under a most favored nation pricing model.
The rollout of TrumpRx.gov marks the most direct effort by the Trump administration to operationalize its most favored nation drug pricing policy.
A long promised initiative intended to lower prescription costs for American patients who often pay more than counterparts abroad.
Under the most favored nation approach, US prices are benchmarked to the lowest prices paid by comparable developed countries.
Trump first advanced the concept during his earlier presidency, arguing that Americans were subsidizing lower drug prices overseas.
The policy gained new momentum after Trump returned to office, culminating in a May 12, 2025, executive order directing agencies to implement the framework.
Since then, the administration has pursued manufacturer agreements rather than direct price controls, a strategy intended to avoid legal challenges.
Centers for Medicare and Medicaid Services Administrator Chiquita Brooks-LaSure said the platform represents “a consumer facing application of international reference pricing that has not previously existed in the US market.”
She noted that participation by manufacturers is voluntary but incentivized by market access.
Richard Frank, a health economist at Harvard Medical School, said the initiative could meaningfully lower prices for certain drugs while leaving broader market dynamics unchanged.
“This does not restructure the pharmaceutical pricing system, but it does introduce a credible external benchmark,” he said.
| Drug | Previous Monthly Price | TrumpRx.gov Price Range |
|---|---|---|
| Ozempic | $1,028 | $199 to $350 |
| Wegovy injection | $1,349 | $199 to $350 |
| Zepbound | $1,088 | $299 to $346 |
| Insulin Lispro | Varies | As low as $25 |
| Bevespi Aerosphere | $458 | $51 |
Novo Nordisk spokesperson Ken Henderson said the company joined TrumpRx.gov to “expand access while maintaining investment in research.”
Pfizer Chief Policy Officer Sally Susman said the program reflects “a negotiated balance between affordability and innovation.”
Patient advocate Maria Torres of the nonprofit Patients for Affordable Drugs said the discounts could be significant for uninsured families. “For people paying cash, these prices change treatment decisions,” she said.
Additional manufacturers that have signed most favored nation agreements are expected to list products on TrumpRx.gov in coming months.
The administration has also urged Congress to codify the pricing framework through proposed health care legislation, which would extend its reach beyond participating manufacturers.
TrumpRx.gov institutionalizes most favored nation pricing as a consumer accessible tool, embedding international price comparisons into the US drug market.
Its long term impact will depend on manufacturer participation and legislative follow through, but the launch establishes a new reference point in the national debate over prescription drug costs.
NOTE! This article was generated with the support of AI and compiled by professionals from multiple reliable sources, including official statements, press releases, and verified media coverage. For more information, please see our T&C.
